Skip to content

Person-checked company records fromPerson-checked records $750See a worked exampleHuman review in progress

Talk to sales

KeptIndex

Johnson & Johnson

Complete the acquisition of Abiomed

Delivered by the deadline

AI-assessed · human review in progress Found and assessed by AI from the cited sources. Shown with its evidence; it is not counted in any Kept Score until confirmed.

Announced
1 Nov 2022
Due
31 Mar 2023
Delivered
22 Dec 2022
  • Deadline
  • Met
  • Late
  • Not met
  • Today

What the company said

“The transaction is expected to be completed prior to the end of the first quarter of 2023”
  • SourceJohnson & Johnson Form 8-K press release, 2022-11-01
  • FilingSEC filing index
  • Deadline as statedprior to the end of the first quarter of 2023
  • Deadline used31 Mar 2023, the last day of the stated period
  • TypeTransaction
  • Permanent referenceKI-C-2022-JNJ-004541
    Cite as https://keptindex.org/c/KI-C-2022-JNJ-004541/ — this address never changes.

What we found

Evidence strength A What the grades mean

Johnson & Johnson completed the acquisition of Abiomed on December 22, 2022, which is prior to the first quarter of 2023 deadline.

  • A
    Johnson & Johnson 10-Q filed 2023-04-28 Regulatory filing · published 28 Apr 2023 · retrieved 3 Oct 2026 · kept permanently by the SEC · fingerprint 560ddb486b80
    “On December 22, 2022, the Company completed the acquisition of Abiomed” ✓ confirmed on the page

Market reaction: the shares moved +1.6% against the S&P 500 over the three sessions around the disclosure (27 Apr 2023 to 2 May 2023). What this measures

Checked 3 Oct 2026.

Commitment DNA

The structured record of this commitment. Fields the company did not state are left blank rather than guessed.

Event type
Acquisition close
Indicative materiality
High rules
Action
Complete
Deliverable
Acquisition of Abiomed
Language
Expected (“expects”, “plans”)
In the company’s control
Medium
Specificity
High
Conditional
Yes: tender of a majority of the outstanding shares of Abiomed’s common stock; receipt of applicable regulatory approvals; customary closing conditions
Depends on
Regulatory, Shareholder, Counterparty

How this entry was checked

  1. Commitment recordedThe company's words were matched word for word against the filing.
  2. First checkAn AI model, Gemini (Google), read the company's later filings and recorded the outcome with a quoted passage.
  3. Second check: agreesA different AI model, Claude (Anthropic), re-read the evidence without being told the outcome and reached the same answer.

Not yet confirmed. Shown on the record, but it will not count in any score until it is confirmed. How verification works

Are you Johnson & Johnson? You can publish an official statement next to this entry, free. Add a statement.

Is something here wrong or out of date? Companies and readers can ask us to check it. Please bring a link to a public source.

Report an error in this entry Reference: KI-C-2022-JNJ-004541 · Corrections policy

The Deadline Report

One email a week: the corporate commitments that came due, which were met, which slipped, and what is due next. Free. Stop any time.

No advertising. We never sell or share your address.